Nasdaq adds Moderna stock to Nasdaq-100

Published on 10/02/2026 at 14:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq will include Moderna on October 9, 2026. Moderna stock costs EUR 169.61 on October 2, 2026 after EUR 168.47, plus 0.68 percent.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Moderna, Inc. stock (ISIN US60770K1079) was trading at EUR 169.61 at Lang & Schwarz on October 2, 2026 at 2:35 p.m. CEST, up 0.68 percent from the EUR 168.47 prior close. The latest company-specific catalyst is an index change: Nasdaq announced on October 1, 2026, that Moderna will join the Nasdaq-100 before market open on October 9, 2026.

Index addition meets valuation pressure

The inclusion gives Moderna a fresh index milestone after a powerful 2026 rerating, but it does not remove the valuation debate. Yahoo Finance reported on September 30, 2026, that Citigroup cut Moderna from Hold to Sell while raising its price target from USD 60.00 to USD 80.00.

The new target still sits well below the recent US listing price. The Nasdaq quote was last at USD 188.94 on October 1, 2026 at 4:00 p.m. ET, while the 52-week range was USD 22.28 to USD 208.90 and market capitalization was USD 75.0 billion.

Second-quarter loss remains central

Moderna's operating picture remains important alongside the index change. In the second quarter of 2026, the company reported revenue of USD 0.1 billion, a GAAP net loss of USD 0.8 billion and GAAP earnings per share of minus USD 1.97, according to Moderna in its September 2026 press-release archive.

The company also reiterated a plan to deliver revenue growth of up to 10 percent in 2026. That outlook contrasts with the second-quarter loss and explains why the oncology pipeline remains a key part of the market narrative rather than a completed earnings engine.

Nasdaq inclusion sets the next date

For Moderna, October 9, 2026 creates a concrete market-structure date, while October 24, 2026 is scheduled for a company investor event tied to late-breaking melanoma data. The combination places index mechanics beside a clinical milestone, with the latest quarterly figures still showing the financial distance to sustained profitability.

Moderna was trading at EUR 169.61 at Lang & Schwarz on October 2, 2026 at 2:35 p.m. CEST, plus 0.68 percent versus the EUR 168.47 prior close. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.